Table 1.
Baseline characteristics of all participants.
| Baseline characteristics | Autoimmune gastritis (N = 31) | Non-autoimmune gastritis (N = 301) | P-value* |
|---|---|---|---|
| Male, N (%) | 18 (58.1) | 162 (53.8) | 0.652 |
| Age, years, median (IQR) | 73 (66–76) | 70 (63–75) | 0.132 |
| Gastric cancer, N (%) | 2/31 (6.5%) | 8/301 (2.7%) | 0.237 |
| Pepsinogen I (ng/mL), median (IQR) | 6.4 (3.8–15.9) | 43.3 (31.2–59.5) | < 0.001* |
| Pepsinogen II (ng/mL), median (IQR) | 7.7 (4.9–10.3) | 8.3 (5.6–13.0) | 0.273 |
| Pepsinogen I/II ratio, median (IQR) | 1.0 (0.6–1.5) | 5.5 (3.6–7.2) | < 0.001* |
| H. pylori antibody titer > 10 U/mL, N (%) | 4/31 (12.9%) | 105/301 (34.9%) | < 0.05* |
|
H. pylori infection status Uninfected/present infection/eradicated/past infection, N (%) |
17/6/8/0 (54.9%/19.4%/25.8%/0%) | 77/106/89/29 (25.6%/35.2%/29.6%/9.6%) | < 0.01* |
| Gastrin (pg/mL), median (IQR) | 1,310 (448–2,490) | 102.0 (82–144) | < 0.001* |
| < 100/100–350/350–1,000/ > 1,000 pg/mL, N (%) | 2/3/7/19 (6.5%/9.7%/22.6%/61.3%) | 141/140/15/5 (46.8%/46.5%/5.0%/1.7%) | < 0.001* |
| Anti-parietal cell antibody positive, N (%) | 29/31 (93.5%) | 0/301 (0%) | < 0.001* |
| Anti-intrinsic factor antibody positive, N (%) | 15/27 (55.6%) | NA | NA |
|
Endoscopic atrophic border†, N (%) C0/C1–3/O1–2/O3/O4, N |
0/2/2/7/20 (0%/6.5%/6.5%/22.6%/64.5%) | 71/67/132/22/9 (23.5%/22.3%/43.9%/7.3%/3.0%) | < 0.001* |
| Endoscopic atrophic border† > O3, N (%) | 27/31 (87.1%) | 31/301 (10.2%) | < 0.001* |
| Disappearance of the gastric fold, N (%) | 19/31 (61.2%) | 20/301 (6.6%) | < 0.001* |
Data are provided as numbers (%) or median (interquartile range [IQR]).
*P-value: Fisher’s exact test or Man–Whitney U test; autoimmune gastritis vs. non-autoimmune gastritis.
†Endoscopic atrophic border was based on the Kimura–Takemoto classification. We defined O4 as marked vascular visibility observed in the greater curvature of the corpus, which is defined as O3 in the Kimura–Takemoto classification.